All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-12-12T14:57:45.000Z

Practice-changing abstracts in indolent lymphoma presented at ASH 2019

By Elina Simanovits, Alia Mohamed
Featured
Gilles Salles
Dec 12, 2019
Share:

Bookmark this article

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Gilles Salles, South Lyon University Hospital Complex, Lyon, FR. We asked Gilles Salles to summarize the practice-changing abstracts in indolent lymphoma presented at ASH 2019.

Gilles Salles talks about important emerging therapies that are being explored in patients with indolent lymphomas such as bispecific antibodies. He also discusses the results of the AUGMENT study and explains the patient outcomes. Gilles Salles also talks about the novel agent, tazemetostat, and discusses the patient responses.

Practice-changing abstracts in indolent lymphoma presented at ASH 2019

More about...
ASH 2019AUGMENTFollicular lymphomaIndolent B-cell lymphomasLenalidomideObinutuzumabRituximabT-cell engagers

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Novel therapies for relapsed/refractory follicular lymphoma: Key updates from ICML 2023

A summary of updates from five key trials, including ROSEWOOD, TRANSCEND and ELM-2, on novel therapeutic agents for the treatment of patients with R/R FL,...

Jul 27, 2023
Add bookmark

Novel therapies for relapsed/refractory follicular lymphoma: Key updates from ICML 2023

A summary of updates from five key trials, including ROSEWOOD, TRANSCEND and ELM-2, on novel therapeutic agents...

Jul 27, 2023
Add bookmark

New chemotherapy-free approaches for the treatment of lymphoid malignancies

At the 15th International Conference on Malignant Lymphoma, the Lymphoma Hub Satellite Symposium highlighted recent advances in chemotherapy-free options in the field of...

Jul 30, 2019
Add bookmark

New chemotherapy-free approaches for the treatment of lymphoid malignancies

At the 15th International Conference on Malignant Lymphoma, the Lymphoma Hub Satellite Symposium highlighted recent advances...

Jul 30, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox